Stocktoria
Septerna, Inc. SEPN
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2024-10-25
Septerna, Inc. financials (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Revenue | $46.0M | $1.1M | $151,000 |
| R&D expense | $97.6M | $65.3M | $36.0M |
| Operating income | -$68.3M | -$80.8M | $2.1M |
| Income tax | $12,000 | -$498,000 | $691,000 |
| Net income | -$48.9M | -$71.8M | $4.2M |
| EPS (diluted) | $-1.10 | $-7.26 | $0.29 |
| Operating cash flow | $110.2M | -$67.5M | -$38.7M |
| Free cash flow | $109.7M | -$69.6M | -$41.6M |
| Cash & equivalents | $120.7M | $238.2M | $88.5M |
| Total assets | $596.2M | $456.6M | $130.9M |
| Total liabilities | $214.3M | $36.5M | $20.0M |
| Shareholders' equity | $381.9M | $420.0M | -$38.4M |
Source: SEC EDGAR filings · CIK 0001984086 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.